Please assess the completion status of the following clinical trial:

Trial Title: Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Patients with confirmed histological or cytological diagnosis of advanced solid tumours and for whom no proven therapy exists or who are not amenable to established treatments.~2. Age 18 years or older.~3. Life expectancy of at least three months.~4. Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.~5. Patients previously treated and with asymptomatic brain metastases are eligible~6. Patients must have recovered from recent surgery.~Exclusion criteria:~1. Active infectious disease~2. Recent surgery within the last 4 weeks prior visit 1.~3. Chronic diarrhoea or gastrointestinal tract disease resulting in an inability to take oral medication~4. History of haemorrhagic or thrombotic events~5. Significant cardiovascular diseases within~6. Current peripheral neuropathy \> Common Terminology Criteria for Adverse Events (CTCAE) grade 1 except due to trauma~7. Untreated or symptomatic brain metastases or leptomeningeal disease.~8. Treatment with an Epidermal growth Factor-receptor (EGFR)- or Heregulin Receptor 2 (HER2) inhibiting drug or antiangiogenic drug.~9. Therapeutic anticoagulation.~10. Female patients of childbearing potential.~11. Known pre-existing interstitial lung disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIBW 2992 + BIBF 1120 (Type: EXPERIMENTAL): This is a phase I dose escalation clinical trial and the data obtained shall determine the MTD for the combination of BIBW 2992/BIBF 1120 in 28-day of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).